目的基于数据挖掘,分析以黄芪为核心的方剂治疗气虚血瘀型卒中的用药规律,运用网络药理学探讨含黄芪核心药物组治疗该病的作用机制。方法以中国学术期刊全文数据库、万方数据知识服务平台、维普生物医学数据库、中国生物医学文献数据库...目的基于数据挖掘,分析以黄芪为核心的方剂治疗气虚血瘀型卒中的用药规律,运用网络药理学探讨含黄芪核心药物组治疗该病的作用机制。方法以中国学术期刊全文数据库、万方数据知识服务平台、维普生物医学数据库、中国生物医学文献数据库、PubMed、Web of Science等中英文数据库收录的相关文献为数据来源,使用Microsoft Excel 2019建立数据库,基于Apriori算法进行关联规则分析,将满足支持度≥0.55、置信度≥0.9药对作为黄芪核心药物组,通过网络药理学探究黄芪核心药物组治疗该病症的作用机制并借助分子对接加以验证。结果最终纳入86首目标方剂,涉及138味中药,累计使用频次908次,关联规则分析结果表明黄芪与川芎、当归、地龙、红花、赤芍具有强关联性,以这6味中药组成的核心药物组共含有89种成分和165个潜在靶点,其中107个潜在靶点分布在神经系统,关键靶点包含丝氨酸/苏氨酸激酶1(AKT1)、血清白蛋白(ALB)、肿瘤坏死因子(TNF)、白细胞介素-6(IL6)、白细胞介素-1β(IL1B)等。基因本体(GO)功能分析主要涉及调节能量代谢、炎症应答、细胞凋亡等生物过程;京都基因与基因组百科全书(KEGG)通路富集分析中磷脂酰肌醇3-激酶-蛋白激酶(PI3K-Akt)、MAPK、IL-17、TNF等通路与核心药物组治疗气虚血瘀型卒中密切相关。分子对接结果显示豆甾醇、β-谷甾醇、槲皮素及汉黄芩素与关键靶蛋白具有较高的结合活性。结论该研究归纳总结了含黄芪方剂治疗气虚血瘀型卒中的用药配伍规律,得到1个黄芪核心药物组,并且在分子水平揭示了黄芪核心药物组治疗该病症的机制,为后续含黄芪方剂治疗该病症的开发提供了数据支撑。展开更多
目的:建立益心泰颗粒的HPLC指纹图谱,为其质量评价提供依据。方法:采用Phenomenext Luna C_(18)色谱柱(250 mm×4.6 mm,5μm),以0.1%磷酸溶液-甲醇为流动相,检测波长为286 nm,体积流量为1.0 m L·min^(-1);柱温为30℃。测定10...目的:建立益心泰颗粒的HPLC指纹图谱,为其质量评价提供依据。方法:采用Phenomenext Luna C_(18)色谱柱(250 mm×4.6 mm,5μm),以0.1%磷酸溶液-甲醇为流动相,检测波长为286 nm,体积流量为1.0 m L·min^(-1);柱温为30℃。测定10批益心泰颗粒样品,应用中药色谱指纹图谱相似度评价系统(2012版)建立益心泰颗粒指纹图谱共有模式图,并计算相似度,再通过对照品色谱图对共有峰进行指认。结果:通过10批样品的测定,建立益心泰颗粒HPLC指纹图谱,计算得相似度为0.98。共标定31个共有色谱峰,其中4个共有峰19、25、30、31号峰为黄芪药材的专属峰;7个共有峰3、20、21、22、23、24、28号峰为丹参的专属峰;9个共有峰6、7、11、12、13、14、26、27、29号峰为红花的专属峰;6个共有峰8、10、15-18号峰为葶苈子的专属峰;1个共有峰5号峰为泽泻专属峰;1、9号峰为红花、泽泻的共有峰,2号峰为红花、茯苓的共有峰,4号峰为猪苓、丹参的共有峰。并通过对照品色谱图对共有峰进行指认,12、19、21、25、30号峰分别为羟基红花黄色素A、毛蕊异黄酮苷、丹酚酸B、芒柄花素、毛蕊异黄酮。结论:10批样品相似度结果表明该颗粒制备工艺方法稳定可行,同时建立的HPLC指纹图谱方法稳定可靠。展开更多
Objective: The objective of this study was to investigate the mechanisms underlying anti-embolism and extravasational effects of traditional Chinese medical prescription YiqiHuoxue(YQHX) formula in ApoE-/-mice with ce...Objective: The objective of this study was to investigate the mechanisms underlying anti-embolism and extravasational effects of traditional Chinese medical prescription YiqiHuoxue(YQHX) formula in ApoE-/-mice with cerebral vascular microemboli. Materials and Methods: An ApoE-/-mice model with microemboli was developed by infusing fluorescently labeled heterologous fibrin-rich microparticles into the internal carotid artery of ApoE -/-gene knockout male mice through the common carotid artery. Before microemboli injection, the animals were randomly divided into four groups of 10 animals, treated daily for 6 weeks by intragastric administration: The ApoE-/-control group(physiological saline, 0.2 mL/10 g/d), YQHX group(0.2 ml/10 g/d), clopidogrel group(3 mg/kg/d), and atorvastatin group(3 mg/kg/d);a further group was constituted of normal male C57 BL/6 J mice(with the same genetic background as ApoE-/-mice;normal control group;no treatment;microemboli injection). The mice in each microemboli group were divided into three subgroups, the 2-h, 24-h, and 72-h subgroups, corresponding to the time after microemboli injection. Two hours(or 24 h or 72 h) after microemboli injection, the changes in aortic intima and brain tissue were analyzed by histopathology, the amounts of fluorescent emboli being measured by fluorescence microscopy image analysis. Comparison points included the microemboli induced loss of aorta functions and pathological changes, atherosclerotic plaque, brain ultrastructure and functions, and embolus extravasation. Results: Loss of aorta functions and adverse pathological changes, atherosclerotic plaque, serious damage in brain ultrastructure and functions, and reduced thrombus elimination were obviously serious in microemboli injected ApoE-/-mice. These symptoms were significantly relieved by the YQHX pretreatment:(i) the ratio of thrombus accumulation was increased with a significant decrease in thrombus extravasation in ApoE-/-mice, while YQHX induced an increased thrombus extravasation;(ii) the degree of aortic intimal thickening and brain tissue structural disorders were significantly increased in ApoE-/-mice, but overtly inhibited in the YQHX group;(iii) YQHX restored cell viability and homeostasis in the brain;(iv) YQHX regulated the expression of pro-and anti-inflammatory cytokines in the aorta;and(v) YQHX reduced cortical nerve nuclei pyknosis, edema, liquefaction, and necrosis induced by brain hypoxia, especially in the 24 h and 72 h groups. Conclusions: These findings indicate that the protective effects of YQHX on the brain against microemboli-induced injury may be attributed to the activation of extravasation mechanisms, which are involved in the cerebrovascular injury pathway and constitutively important in the progression of ischemic stroke.展开更多
文摘目的基于数据挖掘,分析以黄芪为核心的方剂治疗气虚血瘀型卒中的用药规律,运用网络药理学探讨含黄芪核心药物组治疗该病的作用机制。方法以中国学术期刊全文数据库、万方数据知识服务平台、维普生物医学数据库、中国生物医学文献数据库、PubMed、Web of Science等中英文数据库收录的相关文献为数据来源,使用Microsoft Excel 2019建立数据库,基于Apriori算法进行关联规则分析,将满足支持度≥0.55、置信度≥0.9药对作为黄芪核心药物组,通过网络药理学探究黄芪核心药物组治疗该病症的作用机制并借助分子对接加以验证。结果最终纳入86首目标方剂,涉及138味中药,累计使用频次908次,关联规则分析结果表明黄芪与川芎、当归、地龙、红花、赤芍具有强关联性,以这6味中药组成的核心药物组共含有89种成分和165个潜在靶点,其中107个潜在靶点分布在神经系统,关键靶点包含丝氨酸/苏氨酸激酶1(AKT1)、血清白蛋白(ALB)、肿瘤坏死因子(TNF)、白细胞介素-6(IL6)、白细胞介素-1β(IL1B)等。基因本体(GO)功能分析主要涉及调节能量代谢、炎症应答、细胞凋亡等生物过程;京都基因与基因组百科全书(KEGG)通路富集分析中磷脂酰肌醇3-激酶-蛋白激酶(PI3K-Akt)、MAPK、IL-17、TNF等通路与核心药物组治疗气虚血瘀型卒中密切相关。分子对接结果显示豆甾醇、β-谷甾醇、槲皮素及汉黄芩素与关键靶蛋白具有较高的结合活性。结论该研究归纳总结了含黄芪方剂治疗气虚血瘀型卒中的用药配伍规律,得到1个黄芪核心药物组,并且在分子水平揭示了黄芪核心药物组治疗该病症的机制,为后续含黄芪方剂治疗该病症的开发提供了数据支撑。
文摘目的:建立益心泰颗粒的HPLC指纹图谱,为其质量评价提供依据。方法:采用Phenomenext Luna C_(18)色谱柱(250 mm×4.6 mm,5μm),以0.1%磷酸溶液-甲醇为流动相,检测波长为286 nm,体积流量为1.0 m L·min^(-1);柱温为30℃。测定10批益心泰颗粒样品,应用中药色谱指纹图谱相似度评价系统(2012版)建立益心泰颗粒指纹图谱共有模式图,并计算相似度,再通过对照品色谱图对共有峰进行指认。结果:通过10批样品的测定,建立益心泰颗粒HPLC指纹图谱,计算得相似度为0.98。共标定31个共有色谱峰,其中4个共有峰19、25、30、31号峰为黄芪药材的专属峰;7个共有峰3、20、21、22、23、24、28号峰为丹参的专属峰;9个共有峰6、7、11、12、13、14、26、27、29号峰为红花的专属峰;6个共有峰8、10、15-18号峰为葶苈子的专属峰;1个共有峰5号峰为泽泻专属峰;1、9号峰为红花、泽泻的共有峰,2号峰为红花、茯苓的共有峰,4号峰为猪苓、丹参的共有峰。并通过对照品色谱图对共有峰进行指认,12、19、21、25、30号峰分别为羟基红花黄色素A、毛蕊异黄酮苷、丹酚酸B、芒柄花素、毛蕊异黄酮。结论:10批样品相似度结果表明该颗粒制备工艺方法稳定可行,同时建立的HPLC指纹图谱方法稳定可靠。
基金partially supported by the grants from the key R and D Program Project of Shaanxi Science and Technology (No. 2017SF-348)the Innovation funding Project of Science and Technology Commission of Shanghai Pudong New area (No. PKJ2015-Y47)+3 种基金the Research Fund Project of Health and Family Planning Commission of Shaanxi Province (NO.2016D059)the key basic Project of Xinlitai Pharmaceutical Industry (No. 2016XLT01)the Project of Health and Family Planning Commission of Shanghai Pudong New area (No. PDZYXK-2-2014005PDZYK-4-2014002)。
文摘Objective: The objective of this study was to investigate the mechanisms underlying anti-embolism and extravasational effects of traditional Chinese medical prescription YiqiHuoxue(YQHX) formula in ApoE-/-mice with cerebral vascular microemboli. Materials and Methods: An ApoE-/-mice model with microemboli was developed by infusing fluorescently labeled heterologous fibrin-rich microparticles into the internal carotid artery of ApoE -/-gene knockout male mice through the common carotid artery. Before microemboli injection, the animals were randomly divided into four groups of 10 animals, treated daily for 6 weeks by intragastric administration: The ApoE-/-control group(physiological saline, 0.2 mL/10 g/d), YQHX group(0.2 ml/10 g/d), clopidogrel group(3 mg/kg/d), and atorvastatin group(3 mg/kg/d);a further group was constituted of normal male C57 BL/6 J mice(with the same genetic background as ApoE-/-mice;normal control group;no treatment;microemboli injection). The mice in each microemboli group were divided into three subgroups, the 2-h, 24-h, and 72-h subgroups, corresponding to the time after microemboli injection. Two hours(or 24 h or 72 h) after microemboli injection, the changes in aortic intima and brain tissue were analyzed by histopathology, the amounts of fluorescent emboli being measured by fluorescence microscopy image analysis. Comparison points included the microemboli induced loss of aorta functions and pathological changes, atherosclerotic plaque, brain ultrastructure and functions, and embolus extravasation. Results: Loss of aorta functions and adverse pathological changes, atherosclerotic plaque, serious damage in brain ultrastructure and functions, and reduced thrombus elimination were obviously serious in microemboli injected ApoE-/-mice. These symptoms were significantly relieved by the YQHX pretreatment:(i) the ratio of thrombus accumulation was increased with a significant decrease in thrombus extravasation in ApoE-/-mice, while YQHX induced an increased thrombus extravasation;(ii) the degree of aortic intimal thickening and brain tissue structural disorders were significantly increased in ApoE-/-mice, but overtly inhibited in the YQHX group;(iii) YQHX restored cell viability and homeostasis in the brain;(iv) YQHX regulated the expression of pro-and anti-inflammatory cytokines in the aorta;and(v) YQHX reduced cortical nerve nuclei pyknosis, edema, liquefaction, and necrosis induced by brain hypoxia, especially in the 24 h and 72 h groups. Conclusions: These findings indicate that the protective effects of YQHX on the brain against microemboli-induced injury may be attributed to the activation of extravasation mechanisms, which are involved in the cerebrovascular injury pathway and constitutively important in the progression of ischemic stroke.
